Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
May 26, 2020 at 05:30 pm IST
Share
Relmada Therapeutics, Inc. announced the appointment of Molly Harper as Executive Vice President of Operations. Ms. Harper will oversee operations across the functions of the Company. Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Ms. Harper comes to Relmada most recently from Akcea Therapeutics, a development and commercialization company focused on helping patients living with serious and rare diseases, where she most recently served as Senior Vice President and Global Franchise General Manager.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.